The Manufacturers Life Insurance Company Raises Stock Holdings in Cencora, Inc. $COR

The Manufacturers Life Insurance Company boosted its position in shares of Cencora, Inc. (NYSE:COR) by 12.9% in the second quarter, according to the company in its most recent filing with the SEC. The firm owned 1,061,784 shares of the company’s stock after acquiring an additional 121,602 shares during the quarter. The Manufacturers Life Insurance Company owned about 0.55% of Cencora worth $318,376,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Atlantic Edge Private Wealth Management LLC raised its stake in shares of Cencora by 70.0% in the second quarter. Atlantic Edge Private Wealth Management LLC now owns 85 shares of the company’s stock worth $25,000 after purchasing an additional 35 shares during the last quarter. Grove Bank & Trust lifted its stake in Cencora by 4.3% during the 2nd quarter. Grove Bank & Trust now owns 879 shares of the company’s stock valued at $264,000 after acquiring an additional 36 shares during the period. Quadcap Wealth Management LLC boosted its holdings in shares of Cencora by 1.5% in the 2nd quarter. Quadcap Wealth Management LLC now owns 2,409 shares of the company’s stock valued at $722,000 after acquiring an additional 36 shares during the last quarter. U.S. Capital Wealth Advisors LLC increased its stake in shares of Cencora by 0.4% in the second quarter. U.S. Capital Wealth Advisors LLC now owns 8,547 shares of the company’s stock worth $2,563,000 after acquiring an additional 38 shares during the period. Finally, Monument Capital Management raised its holdings in shares of Cencora by 2.4% during the second quarter. Monument Capital Management now owns 1,637 shares of the company’s stock worth $491,000 after purchasing an additional 38 shares during the last quarter. 97.52% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Cencora

In other Cencora news, CEO Robert P. Mauch sold 5,096 shares of the stock in a transaction that occurred on Tuesday, November 18th. The stock was sold at an average price of $366.64, for a total transaction of $1,868,397.44. Following the completion of the transaction, the chief executive officer owned 65,746 shares of the company’s stock, valued at $24,105,113.44. This represents a 7.19% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Chairman Steven H. Collis sold 31,350 shares of the firm’s stock in a transaction that occurred on Tuesday, September 16th. The shares were sold at an average price of $289.86, for a total value of $9,087,111.00. Following the completion of the transaction, the chairman owned 305,913 shares in the company, valued at approximately $88,671,942.18. This trade represents a 9.30% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 46,640 shares of company stock valued at $14,099,338. 10.80% of the stock is owned by company insiders.

Cencora Trading Up 1.0%

Shares of NYSE:COR opened at $340.63 on Thursday. The business’s 50 day moving average price is $341.71 and its 200-day moving average price is $310.60. Cencora, Inc. has a 1 year low of $223.92 and a 1 year high of $377.54. The firm has a market capitalization of $66.08 billion, a price-to-earnings ratio of 42.85, a price-to-earnings-growth ratio of 1.60 and a beta of 0.63. The company has a debt-to-equity ratio of 4.32, a current ratio of 0.90 and a quick ratio of 0.55.

Cencora (NYSE:COR) last issued its quarterly earnings results on Wednesday, November 5th. The company reported $3.84 EPS for the quarter, topping the consensus estimate of $3.79 by $0.05. Cencora had a net margin of 0.48% and a return on equity of 227.15%. The company had revenue of $83.73 billion during the quarter, compared to analyst estimates of $83.36 billion. During the same quarter in the previous year, the firm earned $3.34 EPS. The firm’s revenue was up 5.9% compared to the same quarter last year. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. On average, equities research analysts forecast that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, December 1st. Investors of record on Friday, November 14th were issued a $0.60 dividend. This represents a $2.40 annualized dividend and a yield of 0.7%. The ex-dividend date was Friday, November 14th. This is a positive change from Cencora’s previous quarterly dividend of $0.55. Cencora’s payout ratio is presently 30.19%.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the company. Wall Street Zen downgraded Cencora from a “buy” rating to a “hold” rating in a research report on Friday, November 28th. JPMorgan Chase & Co. lifted their price target on Cencora from $344.00 to $417.00 and gave the company an “overweight” rating in a research report on Tuesday, November 11th. Barclays started coverage on Cencora in a research report on Monday. They issued an “overweight” rating and a $400.00 price objective on the stock. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Cencora in a report on Monday. Finally, Mizuho increased their price target on shares of Cencora from $340.00 to $380.00 and gave the stock an “outperform” rating in a report on Thursday, November 6th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $373.50.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.